Photocure ASA: Results for the third quarter of 2024

Photocure Norway

Erik Dahl
Chief Financial Officer
Email: [e-mail]

David Moskowitz
Vice President of Investor Relations
Tel: [phone]
Email: [e-mail] 

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: [phone]
Email: [e-mail] 

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.  This stock exchange announcement was published by Tolv Hillestad, Group Controller, Photocure ASA, on 13 November 2024 at 08:00 CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/photocure-asa--results-for-the-third-quarter-of-2024,c4065543

The following files are available for download:

https://mb.cision.com/Main/17498/4065543/3110583.pdf

Release

https://mb.cision.com/Public/17498/4065543/860ae291097f5799.pdf

PHO Q3 2024 REPORT

https://mb.cision.com/Public/17498/4065543/9430740bef4cf21b.pdf

PHO Q3 2024 PRESENTATION

 

View original content:https://www.prnewswire.co.uk/news-releases/photocure-asa-results-for-the-third-quarter-of-2024-302303824.html